Streetbeat News

Price Targets

AYX

Alteryx (NYSE:AYX) has received 8 analyst ratings in the last quarter with an average price target of $45.0, representing an upside from the current price of $37.3. The ratings include 4 bullish, 1 somewhat bullish, 1 indifferent, and 2 somewhat bearish. Over the past month, the average price target has increased by 38.46%. Analysts typically review stocks quarterly or after major company updates, basing their ratings on financial predictions and company performance.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 1:00 pm

ALLK

Barclays analyst Carter Gould has maintained an Underweight rating on Allakos (NASDAQ:ALLK) and reduced the price target from $2.5 to $1.5.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 12:59 pm

ANSS

B of A Securities analyst Andrew Obin has downgraded Ansys (NASDAQ:ANSS) from Buy to Underperform and reduced the price target from $356 to $295.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 12:43 pm

SKIN

TD Cowen analyst Oliver Chen downgraded Beauty Health (NASDAQ:SKIN) from Outperform to Market Perform and reduced the price target from $9 to $2.5, indicating a more cautious outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 12:38 pm

ANF

AZPN

BNTX

CARA

MNDY

MOS

PASG

SGRY

SJM

SKIN

Wall Street analysts have updated their price targets and ratings for several companies. Keybanc raised monday.com's target, while Raymond James, Bernstein, Barclays, Baird, Piper Sandler, Canaccord Genuity, TD Cowen, and HC Wainwright & Co. made various adjustments for other firms. These changes could influence the stock performance in the short term.

Portfolio Pulse from Lisa Levin

November 14, 2023 | 12:38 pm

TTWO

Deutsche Bank analyst Bryan Kraft has upgraded Take-Two Interactive (TTWO) from Hold to Buy and increased the price target from $155 to $175, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 12:35 pm

SGRY

TD Cowen analyst Gary Taylor has upgraded Surgery Partners (NASDAQ:SGRY) from Market Perform to Outperform, while also reducing the price target from $39 to $35.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 12:30 pm

AKRO

HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Akero Therapeutics (NASDAQ:AKRO) and maintained a $40 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 12:25 pm

ASUR

Needham analyst Joshua Reilly has reiterated a Buy rating on Asure Software (NASDAQ:ASUR) and maintained a $20 price target on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 12:22 pm

UEC

HC Wainwright & Co. analyst Heiko Ihle has reaffirmed a Buy rating on Uranium Energy Corp (AMEX:UEC) and increased the price target from $8.00 to $8.25.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 12:21 pm